TKT and chronic myelogenous leukemia, BCR-ABL1 positive: Its activity is particularly important, since no other drug is able to inhibit this mutant, which very frequently arises during the treatment with the other TK inhibitors (imatinib, dasatinib, nilotinib and bosutinib) approved for CML and/or Ph+ ALL treatment and confers drug resistance.